comparemela.com

Latest Breaking News On - Vulvovaginal candidiasis - Page 4 : comparemela.com

Hyloris Pharmaceuticals Reports 2022 Half-Year Results and Provides Corporate Update

01.09.2022 - - On track to broaden product pipeline to meet a target portfolio of 30 programs by 2024- Continued commercial rollout of Sotalol IV in US and Maxigesic IV - Focused entry into US market with Maxigesic IV for non-opioid pain treatment; continuing .

Top April 2022 FDA Approvals

April 2022 FDA approvals include treatments for pediatric urinary tract infections, topical rosacea, vulvovaginal candidiasis, and various types of cancer.

SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants

SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

Stock Market | FinancialContent Business Page

Stock Market | FinancialContent Business Page
financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.